Interestingly, overexpression of EGF receptor 2 (ERBB2, HER2) has been demonstrated in primary lung mucinous adenocarcinomas, which were characterized by KRAS activating mutations as well as very high levels of MUC5AC production [33,34]. The gene discussed is KRAS; the disease is mucinous adenocarcinoma.